*Guest blog by Eramol. If you would like to submit a guest blog please email [email protected].
Early-phase clinical programmes often face a different set of challenges compared with late-stage or commercial manufacturing.
Drug substance may be scarce. The formulation may still be evolving. The clinical protocol may require flexibility. The sponsor may need enough finished product for first-in-human studies, dose escalation, cohort expansion, stability, analytical testing and contingency supply.
For this reason, sterile fill-finish strategy needs to be aligned with the realities of early development.
Low line losses can help sponsors:
- maximise the number of finished units from a limited batch
- reduce waste of high-value drug product
- protect scarce API or biologic material
- improve the likelihood of meeting clinical supply targets
- reduce the risk of additional manufacturing runs
- support better planning for stability and retain samples
- protect project timelines
For early-stage biotech companies, the commercial impact can be significant. A small amount of avoidable product loss may represent weeks or months of upstream development work, high API cost, or limited material that cannot be quickly replaced.